Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LabCorp splashes $6bn on drug trial firm Covance

This article was originally published in Clinica

Executive Summary

Laboratory Corporation of America (LabCorp) has agreed to buy drug development specialist Covance in a deal worth around $6.1bn in terms of equity value. The cash-and-stock transaction currently values Covance’s shares at $105.12, a 32% premium over their closing price of $79.90 on 31 October, the last trading day before the purchase was announced. The deal gives Covance an enterprise value of around $5.9bn.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel